Clinical Trial Update: A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of indoximod or placebo plus pembrolizumab or nivolumab in unresectable or metastatic melanoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Indoximod (indoximod)
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2022-09-27